SHENYANG XINGQI PHARMACEUTICAL CO.(SZ:300573)2022-12-03 09:48Company Overview - Shenyang Xingqi Eye Pharmaceutical Co., Ltd. focuses on the research, production, and sales of ophthalmic drugs, primarily prescription medications [2][3]. - The company was established in July 2000 and was listed on the Shenzhen Stock Exchange in December 2016, with the stock code 300573 [4]. Financial Performance - In 2017, the company achieved a revenue of ¥360,006,690.25, representing a year-on-year growth of 6.17% [3]. - The revenue composition includes: - Gel/eye ointment: ¥232,801,419.44 (64.67% of total revenue, up 4.61% YoY) - Eye drops: ¥114,042,238.23 (31.68% of total revenue, up 10.71% YoY) - Solution: ¥12,319,145.16 (3.42% of total revenue) - Other products: ¥843,887.42 (0.23% of total revenue) [3]. Research and Development - The R&D investment in 2017 was ¥31,837,000, accounting for 8.84% of total revenue, an increase of ¥12,251,500 from 2016 [4]. Market Strategy - The company plans to enhance its marketing efforts by increasing the number of first-level distributors and improving academic promotion personnel training [4]. - The strategy includes expanding coverage to more medical institutions and conducting various academic activities to boost product market share [4]. Product Development - The company’s cyclosporine eye drops are included in the priority review process, aimed at treating dry eye syndrome [5]. - The Xiamen Daka project is currently in the preclinical research stage, focusing on tissue-engineered corneas [5].